Apptly Health Technologies Teams Up with Woman-Owned Bryleos to Broaden UberDoc Marketplace Services

Strategic Alliance Enhances UberDoc’s Healthcare Marketplace

On July 28, 2026, Apptly Health Technologies announced from Vancouver, British Columbia, the addition of Bryleos as a strategic partner on the UberDoc marketplace platform. This move represents a key milestone in Apptly’s broader platform strategy to extend the UberDoc direct-access, transparent-pricing model beyond specialist medical care into complementary health and wellness sectors.

The announcement highlights that Bryleos’s integration will offer patients and physicians direct access to the company’s proprietary NAD+ formulations and cellular health products. This partnership aims to provide healthcare providers and patients with credible, research-backed options within a unified marketplace platform. UberDoc will prominently feature Bryleos across its communications, adhering to applicable advertising and endorsement regulations.

Bryleos’s Patent-Pending Technology and Scientific Foundation

As a woman-owned life sciences company, Bryleos introduces its patent-pending LathMizedAE NAD+ platform to UberDoc, targeting metabolic changes linked to aging, recovery, and cellular resilience. The company’s scientific approach is grounded in randomized, placebo-controlled human research published in peer-reviewed literature, aligning with UberDoc’s standards for transparency and credibility.

Bryleos focuses on oral cellular health formulations centered on NAD+ science designed to support healthy cellular metabolism. Featuring Bryleos on UberDoc expands access to science-based wellness and metabolic health options that complement the platform’s existing specialist care services. Specific details regarding Bryleos’s product range and commercial launch timelines on UberDoc were not disclosed.

Apptly’s Platform Strategy and Revenue Growth

This partnership is part of Apptly’s broader platform strategy to develop multiple revenue streams within the UberDoc ecosystem. The company is evolving from a specialist-care marketplace into a comprehensive direct-pay healthcare platform where patients and physicians can access a variety of credible innovations with transparency. Bryleos’s onboarding is a significant step in this diversification.

Dr. Paula M. Muto, Founder and Interim CEO of Apptly, commented: "UberDoc was built on a simple idea, that patients and physicians deserve direct, transparent access to the innovations shaping modern health. Our partnership with Bryleos reflects that same commitment. We are focused on building a trusted, transparent platform where patients and the physicians who serve them can explore credible options in one place, and we are glad to welcome Bryleos into that ecosystem." This statement underscores Apptly’s intent to expand beyond specialist care into adjacent categories while maintaining core values of transparency and direct access.

Bryleos Leadership on Joining UberDoc

Wendy Komac, CEO of Bryleos, explained the company’s motivation for joining UberDoc: "At Bryleos, our mission has always been to translate rigorous scientific research into meaningful support for healthy aging and cellular wellness. Partnering with UberDoc allows us to connect with physicians and patients through an innovative healthcare platform built on transparency, accessibility, and quality care. Together, we have an opportunity to bring the concept of precision nutrition, including science-backed NAD+ support, into more informed conversations about metabolic health and overall wellness."

This highlights Bryleos’s view of UberDoc as a channel to reach healthcare providers and patients seeking validated metabolic health and cellular wellness solutions. The partnership offers a distribution platform for Bryleos’s formulations and provides UberDoc users access to clinically supported cellular health innovations.

Board Member Endorsement and Partner Selection Criteria

John Dvor, Apptly Board member, stated: "As a Board Member, I am proud that the Company is partnering with Bryleos, a woman-owned life sciences company focused on cellular health that has invested in published, peer-reviewed human research. Partnerships like this one expand what patients can discover on the UberDoc marketplace and reflect the standard we intend to hold for every company we bring onto the platform."

This commentary indicates that Apptly applies board-level oversight in selecting marketplace partners, emphasizing rigorous scientific standards and published research. The recognition of Bryleos’s woman-owned status also reflects the company’s commitment to diversity and inclusion in health innovation. The board’s remarks reinforce that marketplace partners must meet defined scientific credibility and transparency standards before onboarding.

UberDoc Platform Reach and Capabilities

The announcement notes that UberDoc connects patients directly with over 5,000 board-certified specialists across 55+ specialties in all 50 U.S. states, offering transparent, upfront pricing without referral requirements, insurance barriers, or surprise bills.

The addition of Bryleos extends UberDoc’s scope beyond traditional specialist medical care into cellular health and wellness. Founded by Dr. Paula M. Muto, M.D., UberDoc aims to provide faster patient access to care while enabling physicians to expand their practices. The Bryleos partnership supports this mission by broadening service categories within the direct-pay, transparent-pricing model.

Medical Advice Disclaimer and Compliance

The announcement clarifies that UberDoc does not provide medical advice; clinical and treatment decisions remain solely between patients and their physicians. This disclaimer emphasizes that while UberDoc facilitates access to Bryleos’s offerings, it does not offer medical guidance or treatment recommendations.

Additionally, Apptly discloses commercial relationships with featured partners in accordance with advertising and endorsement guidelines, ensuring regulatory compliance and transparent communication with users about commercial affiliations. This positioning confirms UberDoc as a marketplace facilitator rather than a healthcare provider.

About Apptly Health Technologies and UberDoc

Apptly Health Technologies Corp. operates UberDoc, a direct-pay healthcare marketplace emphasizing transparent, upfront pricing without referral or insurance barriers and no surprise billing. Founded by Dr. Paula M. Muto, M.D., a practicing vascular surgeon and current Interim CEO, the platform connects patients with board-certified specialists across numerous medical fields.

UberDoc’s expansion into partnerships like Bryleos demonstrates Apptly’s strategy to broaden its value proposition beyond specialist care to include health and wellness categories aligned with its core mission. Apptly is publicly traded on the Canadian Securities Exchange (ticker: APPT) and the Frankfurt Stock Exchange (ticker: 4KL0).

About Bryleos and Its NAD+ Science

Bryleos (BioNADrx Holdings, Inc.) is a woman-owned life sciences company developing proprietary oral NAD+ formulations aimed at supporting healthy cellular metabolism amid aging, recovery, and daily cellular resilience. Its patent-pending LathMizedAE NAD+ platform forms the basis of its product offerings.

The company’s scientific approach is supported by randomized, placebo-controlled human research published in peer-reviewed journals. This research-backed methodology is a key differentiator and a primary reason for partnering with UberDoc. Additional information on Bryleos’s published research is available at bryleos.com, though specific study details were not provided in the announcement.

Forward-Looking Statements and Risk Factors

The announcement contains standard forward-looking statements disclaimers, noting that expectations regarding the partnership’s benefits, Bryleos’s presence on UberDoc, and the company’s growth strategy are subject to risks and uncertainties that could cause actual outcomes to differ materially.

Risk factors include market conditions, business execution challenges, regulatory considerations, and other risks detailed in Apptly’s public filings on SEDAR+. The company disclaims any obligation to update forward-looking information except as required by law and cautions readers against undue reliance on such statements.